BR112022014717A2 - Métodos e composições para a inibição das infecções por vírus da hepatite b e da hepatite d - Google Patents
Métodos e composições para a inibição das infecções por vírus da hepatite b e da hepatite dInfo
- Publication number
- BR112022014717A2 BR112022014717A2 BR112022014717A BR112022014717A BR112022014717A2 BR 112022014717 A2 BR112022014717 A2 BR 112022014717A2 BR 112022014717 A BR112022014717 A BR 112022014717A BR 112022014717 A BR112022014717 A BR 112022014717A BR 112022014717 A2 BR112022014717 A2 BR 112022014717A2
- Authority
- BR
- Brazil
- Prior art keywords
- hepatitis
- methods
- compositions
- virus infections
- inhibition
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 241000700721 Hepatitis B virus Species 0.000 title abstract 2
- 208000037262 Hepatitis delta Diseases 0.000 title abstract 2
- 241000724709 Hepatitis delta virus Species 0.000 title abstract 2
- 208000015181 infectious disease Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000005764 inhibitory process Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 102000008122 Casein Kinase I Human genes 0.000 abstract 1
- 108010049812 Casein Kinase I Proteins 0.000 abstract 1
- 102100037888 DnaJ homolog subfamily B member 12 Human genes 0.000 abstract 1
- 101000805849 Homo sapiens DnaJ homolog subfamily B member 12 Proteins 0.000 abstract 1
- 101000578920 Homo sapiens Microtubule-actin cross-linking factor 1, isoforms 1/2/3/5 Proteins 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000049401 human MACF1 Human genes 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062979442P | 2020-02-21 | 2020-02-21 | |
| PCT/CA2021/050176 WO2021163796A1 (en) | 2020-02-21 | 2021-02-18 | Methods and compositions for the inhibition of hepatitis b and hepatitis d virus infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022014717A2 true BR112022014717A2 (pt) | 2022-10-11 |
Family
ID=77390241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022014717A BR112022014717A2 (pt) | 2020-02-21 | 2021-02-18 | Métodos e composições para a inibição das infecções por vírus da hepatite b e da hepatite d |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230056788A1 (enExample) |
| EP (1) | EP4106768A1 (enExample) |
| JP (1) | JP2023515424A (enExample) |
| KR (1) | KR20220145862A (enExample) |
| CN (1) | CN115087451A (enExample) |
| AU (1) | AU2021224509A1 (enExample) |
| BR (1) | BR112022014717A2 (enExample) |
| CA (1) | CA3164677A1 (enExample) |
| IL (1) | IL295593A (enExample) |
| MX (1) | MX2022010346A (enExample) |
| WO (1) | WO2021163796A1 (enExample) |
| ZA (1) | ZA202208412B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250223325A1 (en) * | 2022-08-08 | 2025-07-10 | Viron, Inc. | Functional porosome manipulation |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2305813A3 (en) * | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| CA2566286A1 (en) * | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same |
| WO2019112489A1 (en) * | 2017-12-05 | 2019-06-13 | Limited Liability Company "Gero" | Methods and agents for treatment of aging and aging related conditions and diseases |
-
2021
- 2021-02-18 WO PCT/CA2021/050176 patent/WO2021163796A1/en not_active Ceased
- 2021-02-18 KR KR1020227032637A patent/KR20220145862A/ko not_active Withdrawn
- 2021-02-18 AU AU2021224509A patent/AU2021224509A1/en active Pending
- 2021-02-18 US US17/792,746 patent/US20230056788A1/en active Pending
- 2021-02-18 MX MX2022010346A patent/MX2022010346A/es unknown
- 2021-02-18 CN CN202180013791.XA patent/CN115087451A/zh active Pending
- 2021-02-18 CA CA3164677A patent/CA3164677A1/en active Pending
- 2021-02-18 IL IL295593A patent/IL295593A/en unknown
- 2021-02-18 BR BR112022014717A patent/BR112022014717A2/pt unknown
- 2021-02-18 JP JP2022549282A patent/JP2023515424A/ja active Pending
- 2021-02-18 EP EP21757260.1A patent/EP4106768A1/en not_active Withdrawn
-
2022
- 2022-07-27 ZA ZA2022/08412A patent/ZA202208412B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN115087451A (zh) | 2022-09-20 |
| MX2022010346A (es) | 2022-10-21 |
| JP2023515424A (ja) | 2023-04-13 |
| CA3164677A1 (en) | 2021-08-26 |
| WO2021163796A1 (en) | 2021-08-26 |
| EP4106768A1 (en) | 2022-12-28 |
| IL295593A (en) | 2022-10-01 |
| AU2021224509A1 (en) | 2022-09-08 |
| US20230056788A1 (en) | 2023-02-23 |
| KR20220145862A (ko) | 2022-10-31 |
| ZA202208412B (en) | 2024-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021023457A2 (pt) | Composto, uso do composto, composição, e, métodos para preparar a composição e um composto | |
| BR112022007867A2 (pt) | Degradadores de pequena molécula de helios e métodos de uso | |
| BR112022010112A2 (pt) | Aminoquinolonas substituídas como inibidores de dgkalfa para ativação imunológica | |
| MX2020013853A (es) | Compuestos innovadores. | |
| MX2021013743A (es) | Subunidad s1 modificada de la proteina de espicula de coronavirus. | |
| BR112022021136A2 (pt) | Composições de irna de fator b de complemento (cfb) e métodos de uso das mesmas | |
| BR112021017049A2 (pt) | Derivados de tiazol como inibidores de secreção de proteínas | |
| MX2020003473A (es) | Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas. | |
| BR112017022349A2 (pt) | ?composto, composição, método, e, método para inibir uma proteína irak? | |
| BR112018075465A2 (pt) | agentes antivirais de hepatite b | |
| BR112018017172A2 (pt) | anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau | |
| WO2019086141A8 (en) | Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv) | |
| BR112021024948A2 (pt) | Moduladores de próxima geração de estimulador de genes de interferon (sting) | |
| MX391339B (es) | Composicion farmaceutica que comprende selexipag. | |
| CU20210088A7 (es) | Compuestos derivados sustituidos de indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) | |
| BR112019000732A2 (pt) | métodos e composições para o tratamento de câncer | |
| BR112021024300A2 (pt) | Formas de sais cristalinas de um inibidor de quinase | |
| BR112021002565A8 (pt) | Composto, sal farmaceuticamente aceitável, tautômero ou estereoisômero do mesmo, composição farmacêutica, processo para a síntese e uso do dito composto | |
| BR112017021529A2 (pt) | composto, composição, método para controlar uma praga e semente tratada | |
| BR112021020883A2 (pt) | Formas sólidas de um inibidor de glyt1 | |
| BR112022001488A2 (pt) | Inibidores de proteínas quinases de pirazolo-piridina substituída com heteroarila para promover regeneração do fígado ou redução ou prevenção de morte de hepatócitos | |
| BR112022010441A2 (pt) | Análogos de equinocandina e método de preparação para os mesmos | |
| BR112023004612A2 (pt) | Derivados de 2-(3-piridin-2-il-4-quinolin-4-il-pirazol-1-il)-acetamida como inibidores de receptor i de fator-beta de crescimento transformador/alk5 | |
| BR112022009058A2 (pt) | Compostos herbicidas | |
| BR112022007207A2 (pt) | Composição farmacêutica que compreende selexipag |